The internal analysis and external of the business likewise can be done through SWOT Analysis, summed up in the Exhibition F.
Strengths
• Novartis Gilenya Navigating The Interplay Between Drug Innovation Pricing And Reimbursement In Different Countries Health Care Systems has an experience of about 140 years, making it possible for business to better perform, in numerous scenarios.
• Nestlé's has existence in about 86 countries, making it a global leader in Food and Drink Industry.
• Novartis Gilenya Navigating The Interplay Between Drug Innovation Pricing And Reimbursement In Different Countries Health Care Systems has more than 2000 brand names, which increase the circle of its target consumers. These brand names consist of child foods, pet food, confectionary items, beverages and so on. Famous brands of Novartis Gilenya Navigating The Interplay Between Drug Innovation Pricing And Reimbursement In Different Countries Health Care Systems consist of; Maggi, Kit-Kat, Nescafe, etc.
• Novartis Gilenya Navigating The Interplay Between Drug Innovation Pricing And Reimbursement In Different Countries Health Care Systems has large quantity of costs on R&D as compare to its competitors, making the company to launch more innovative and healthy products. This development offers the company a high competitive position in long term.
• After adopting its NHW Method, the company has actually done big quantity of mergers and acquisitions which increase the sales development and improve market position of Novartis Gilenya Navigating The Interplay Between Drug Innovation Pricing And Reimbursement In Different Countries Health Care Systems.
• Novartis Gilenya Navigating The Interplay Between Drug Innovation Pricing And Reimbursement In Different Countries Health Care Systems is a widely known brand name with high consumer's commitment and brand recall. This brand commitment of customers increases the chances of easy market adoption of numerous new brand names of Novartis Gilenya Navigating The Interplay Between Drug Innovation Pricing And Reimbursement In Different Countries Health Care Systems.
Weaknesses
• Acquisitions of those company, like; Kraft frozen Pizza business can offer an unfavorable signal to Novartis Gilenya Navigating The Interplay Between Drug Innovation Pricing And Reimbursement In Different Countries Health Care Systems clients about their compromise over their core competency of healthier foods.
• The growth I sales as compare to the business's investment in NHW Strategy are quite various. It will take long to alter the perception of individuals ab out Novartis Gilenya Navigating The Interplay Between Drug Innovation Pricing And Reimbursement In Different Countries Health Care Systems as a company selling healthy and nutritious products.
Opportunities
• Presenting more health associated products enables the company to catch the marketplace in which consumers are rather conscious about health.
• Developing countries like India and China has biggest markets in the world. Expanding the market towards establishing nations can improve the Novartis Gilenya Navigating The Interplay Between Drug Innovation Pricing And Reimbursement In Different Countries Health Care Systems service by increasing sales volume.
• Continue acquisitions and joint ventures increases the market share of the business.
• Increased relationships with schools, hotel chains, restaurants etc. can also increase the number of Novartis Gilenya Navigating The Interplay Between Drug Innovation Pricing And Reimbursement In Different Countries Health Care Systems customers. Instructors can advise their students to acquire Novartis Gilenya Navigating The Interplay Between Drug Innovation Pricing And Reimbursement In Different Countries Health Care Systems products.
Threats
• Financial instability in countries, which are the possible markets for Novartis Gilenya Navigating The Interplay Between Drug Innovation Pricing And Reimbursement In Different Countries Health Care Systems, can develop a number of concerns for Novartis Gilenya Navigating The Interplay Between Drug Innovation Pricing And Reimbursement In Different Countries Health Care Systems.
• Shifting of items from normal to much healthier, causes extra expenses and can cause decrease company's profit margins.
• As Novartis Gilenya Navigating The Interplay Between Drug Innovation Pricing And Reimbursement In Different Countries Health Care Systems has a complicated supply chain, therefore failure of any of the level of supply chain can lead the business to face particular problems.
Exhibit F: SWOT Analysis
